Aucubin Protects against Myocardial Infarction‐Induced Cardiac Remodeling via nNOS/NO‐Regulated Oxidative Stress

Zheng Yang, Qingqing Wu, Yang Xiao, Ming Xia Duan, Chen Liu, Yuan Yuan, Yanyan Meng, Hai Liao, Qizhu TangOxidative 2018 · DOI

TL;DR

This study investigates the protective effects of aucubin, a natural compound, against cardiac remodeling following myocardial infarction (MI) in mice. Researchers found that aucubin significantly improves survival, reduces infarct size, and enhances cardiac function by modulating oxidative stress and activating the nNOS/NO pathway, ultimately inhibiting the pro-inflammatory ASK1/JNK signaling cascade.

What Problem Does This Paper Address?

Myocardial infarction (MI) often leads to adverse cardiac remodeling, a complex process involving inflammation, apoptosis, and fibrosis. This remodeling can result in chamber dilation and further heart failure, posing a significant clinical challenge. While early repair mechanisms are essential, their dysregulation can cause sustained tissue damage. Therefore, identifying therapeutic strategies to effectively manage this detrimental remodeling process is crucial. This paper explores whether aucubin, a compound with known anti-inflammatory and antioxidant properties, can mitigate MI-induced cardiac remodeling.

Methods

The study employed a mouse model of myocardial infarction induced by left anterior descending coronary artery ligation. Key experimental approaches included:

  • In vivo studies: Mice were treated with aucubin post-MI. Outcomes assessed included survival rates, infarct size (using TTC staining), cardiac function (echocardiography and hemodynamics), cardiac hypertrophy and fibrosis (histological analysis including HE and Masson trichrome staining, and measurement of heart/body weight ratios), inflammation and apoptosis (immunohistochemistry for CD45 and CD68, TUNEL assays), oxidative stress markers (ROS detection), and the expression of key signaling proteins (Western blot and RT-PCR).
  • In vitro studies: H9c2 cardiomyocytes were subjected to hypoxic conditions to mimic cellular stress. Aucubin's effects on cell viability, apoptosis, oxidative stress, and signaling pathways were evaluated.
  • Pharmacological interventions: The study utilized specific inhibitors (L-NAME, L-VINO, L-canavanine, SP600125) and activators (anisomycin) to dissect the roles of nitric oxide synthases (NOS) and the ASK1/JNK pathway.
  • Genetic models: nNOS knockout (KO) mice were used to definitively establish the role of nNOS in aucubin's protective effects.

Datasets

Not discussed in the paper. The study primarily relies on experimental data generated from animal models and cell cultures.

Key Insights and Ideas

  • Aucubin as a cardioprotective agent: The study provides strong evidence that aucubin can significantly improve outcomes after MI, not just by preventing damage but by actively promoting recovery and reducing remodeling.
  • The nNOS/NO pathway is central: A major finding is the critical role of neuronal nitric oxide synthase (nNOS) and its product, nitric oxide (NO), in mediating aucubin's protective effects. This highlights a specific molecular target for therapeutic intervention.
  • Oxidative stress as a key mediator: Aucubin's ability to attenuate oxidative stress (reduced ROS production, increased thioredoxin preservation) is a core mechanism through which it exerts its benefits.
  • ASK1/JNK pathway inhibition: The research clearly demonstrates that aucubin's protective effects are linked to the inhibition of the pro-inflammatory and pro-apoptotic ASK1/JNK signaling cascade, which is often activated by oxidative stress.
  • Synergistic effects: The study suggests that aucubin's benefits stem from a coordinated action involving the nNOS/NO pathway, oxidative stress reduction, and subsequent inhibition of the ASK1/JNK pathway.

Key Results

  • Improved Survival and Cardiac Function: Aucubin treatment significantly increased survival rates (from 30% to 61.6% in vehicle-MI vs. aucubin-MI groups) and improved cardiac function (increased LVEF, LVFS, dP/dtmax, dP/dtmin; decreased EDP) 2 weeks post-MI.
  • Reduced Cardiac Remodeling: Aucubin attenuated cardiac hypertrophy and fibrosis, as evidenced by reduced heart/body weight ratios, decreased LV collagen volume, and normalized expression of hypertrophic and fibrotic markers.
  • Inhibition of Inflammation and Apoptosis: Aucubin reduced the infiltration of inflammatory cells (CD45, CD68), decreased pro-inflammatory cytokine expression (TNFa, MCP-1, IL-1), and significantly reduced cardiomyocyte apoptosis (TUNEL assay, decreased Bax/cleaved caspase-3, increased Bcl-2).
  • Attenuation of Oxidative Stress: Aucubin treatment led to decreased ROS production and increased levels of antioxidants like thioredoxin (Trx) and SOD.
  • Activation of nNOS/NO Pathway: Aucubin increased nNOS expression and NO production, while inhibitors of NOS (L-NAME, L-VINO) reversed its protective effects.
  • Inhibition of ASK1/JNK Signaling: Aucubin blocked the activation of ASK1 and JNK, which was confirmed by the use of JNK inhibitors and activators.
  • nNOS KO Abolishes Protection: In nNOS knockout mice, aucubin failed to provide any protective benefits against MI-induced cardiac remodeling, underscoring the essential role of nNOS.

Limitations and Future Work

The authors acknowledge a few limitations:

  • Single Dosage: Only one dosage of aucubin was tested in vivo. Future studies should explore a range of dosages to determine optimal therapeutic levels.
  • Pharmacokinetics: The distribution of aucubin in the blood after intraperitoneal injection and its pharmacokinetic profile were not investigated. This information would be valuable for understanding its systemic effects.
  • Broader Signaling Pathways: While the ASK1/JNK pathway was elucidated, the study suggests further investigation into whether aucubin influences other cell types and signaling pathways involved in cardiac remodeling.

The findings open avenues for developing aucubin-based therapies for MI, but further research is needed to optimize its use and fully understand its complex mechanisms of action.

Summary updated

Abstract

Whether aucubin could protect myocardial infarction- (MI-) induced cardiac remodeling is not clear. In this study, in a mouse model, cardiac remodeling was induced by left anterior descending coronary artery ligation surgery. Mice were intraperitoneally injected with aucubin (10 mg/kg) 3 days post-MI. Two weeks post-MI, mice in the aucubin treatment group showed decreased mortality, decreased infarct size, and improved cardiac function. Aucubin also decreased cardiac remodeling post-MI. Consistently, aucubin protected cardiomyocytes against hypoxic injury in vitro. Mechanistically, we found that aucubin inhibited the ASK1/JNK signaling. These effects were abolished by the JNK activator. Moreover, we found that the oxidative stress was attenuated in both in vivo aucubin-treated mice heart and in vitro-treated cardiomyocytes, which caused decreased thioredoxin (Trx) consumption, leading to ASK1 forming the inactive complex with Trx. Aucubin increased nNOS-derived NO production in vivo and vitro. The protective effects of aucubin were reversed by the NOS inhibitors L-NAME and L-VINO in vitro. Furthermore, nNOS knockout mice also reversed the protective effects of aucubin on cardiac remodeling. Taken together, aucubin protects against cardiac remodeling post-MI through activation of the nNOS/NO pathway, which subsequently attenuates the ROS production, increases Trx preservation, and leads to inhibition of the ASK1/JNK pathway.
BibTeX
@inproceedings{yang2018aucubin,
  author = {Zheng Yang and Qingqing Wu and Yang Xiao and Ming Xia Duan and Chen Liu and Yuan Yuan and Yanyan Meng and Hai Liao and Qizhu Tang},
  title = {{Aucubin Protects against Myocardial Infarction‐Induced Cardiac Remodeling via nNOS/NO‐Regulated Oxidative Stress}},
  booktitle = {Oxidative},
  year = {2018},
  doi = {10.1155/2018/4327901},
}
Figure